Differential expression of chemokine receptors on uveal melanoma cells and their metastases

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 2, 2008, Pages 636-643

  Li, Haochuan ^a   Alizadeh, Hassan ^a   Niederkorn, Jerry Y ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; LIVER EXTRACT; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CHEMOTAXIS; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER METASTASIS; LIVER PARENCHYMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; UVEA MELANOMA; ANIMAL; CELL CULTURE; CELL MOTION; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; UVEA TUMOR;

ANIMALS; CELL MOVEMENT; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTORS, CCR7; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS;

EID: 40649091877     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1035     Document Type: Article

References (52)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32: 239-251.
2. Mahoney MC, Burnett WS, Majerovics A, Tanenbaum H. The epidemiology of ophthalmic malignancies in New York State. Ophthalmology. 1990;97:1143-1147.
3. McCarthy JM, Rootman J, Horsman D, White VA. Conjunctival and uveal melanoma in the dysplastic nevus syndrome. Surv Ophthalmol. 1993;37:377-386.
4. Niederkorn JY. Immunopathogenesis of intraocular tumors. Prog Retinal Eye Res. 1995;14:505-526.
5. Vijayasaradhi S, Houghton AN. Melanoma and melanocytes: pigmentation, tumor progression, and the immune response to cancer. Adv Pharmacol. 1995;32:343-374.
6. Char DH. Metastatic choroidal melanoma. Am J Ophthalmol. 1978;86:76-80.
7. Augsburger JJ, Mullen D, Kleineidam M. Planned combined I-125 plaque irradiation and indirect ophthalmoscope laser therapy for choroidal malignant melanoma. Ophthalmic Surg. 1993;24:76-81.
8. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma [see comments]. Cancer. 1993;72:2219-2223.
9. COMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001;119:670-676.
10. Albert DM. The ocular melanoma story: LIII Edward Jackson Memorial Lecture: Part II. Am J Ophthalmol. 1997;123:729-741.
11. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571-573.
12. Ganju RK, Brubaker SA, Meyer J, et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem. 1998;273:23169-23175.
13. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540-550.
14. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14:171-179.
15. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006; 107:1761-1767.
16. Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119:2026-2029.
17. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744-2753.
18. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
19. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst. 2001;93:1638-1643.
20. Scala S, Ierano C, Ottaiano A, et al. CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol Immunother. 2007; 56:1589-1595.
21. Callender G. Malignant melanotic tumors of the eye: a study of histologic types in 111 cases. Trans Am Ophthalmol Otolaryngol. 1931;36:131-142.
22. Murakami T, Cardones AR, Hwang ST. Chemokine receptors and melanoma metastasis. J Dermatol Sci. 2004;36:71-78.
23. Huang XQ, Mitchell MS, Liggett PE, Murphree AL, Kan-Mitchell J. Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients. Cancer Immunol Immunother. 1994;38:399-405.
24. Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci. 1989;30:829-834.
25. Luyten GP, van der Spek CW, Brand I, et al. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines. Melanoma Res. 1998;8:11-16.
26. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol. 2000;165:710-715.
27. Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med. 2001;193:661-670.
28. Huber TB, Reinhardt HC, Exner M, et al. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol. 2002;168:6244-6252.
29. Dithmar S, Rusciano D, Grossniklaus HE. A new technique for implantation of tissue culture melanoma cells in a murine model of metastatic ocular melanoma. Melanoma Res. 2000;10:2-8.
30. Dithmar S, Rusciano D, Lynn MJ, Lawson DH, Armstrong CA, Grossniklaus HE. Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol. 2000;118:1085-1089.
31. Dithmar SA, Rusciano DA, Armstrong CA, Lynn MJ, Grossniklaus HE. Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res. 1999;19:426- 431.
32. Rusciano D, Lorenzoni P, Burger M. Murine models of liver metastasis. Invasion Metastasis. 1994;14:349-361.
33. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986;123:195-203.
34. Steuhl KP, Rohrbach JM, Knorr M, Thiel HJ. Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology. 1993;100:208-215.
35. Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev. 1986;5:29-49.
36. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med. 2001;345:833-835.
37. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002;62:5930-5938.
38. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89:462-473.
39. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002;277:49481-49487.
40. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003;425:307-311.
41. Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z. Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun. 2006;346:252-258.
42. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003;167:1676-1686.
43. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003;100:13513-13518.
44. Scala S, Giuliano P, Ascierto PA, et al. Human melanoma metastases express functional CXCR4. Clin Cancer Res. 2006;12:2427-2433.
45. Samara GJ, Lawrence DM, Chiarelli CJ, et al. CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett. 2004;214:231-241.
46. Singh S, Singh UP, Grizzle WE, Lillard JW Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metallopro-teinase expression and invasion. Lab Invest. 2004;84:1666-1676.
47. El-Shabrawi Y, Ardjomand N, Radner H, Ardjomand N. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J Pathol. 2001;194:201-206.
48. Vaisanen A, Kallioinen M, von Dickhoff K, Laatikainen L, Hoyhtya M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein-a new prognostic marker in uveal melanoma? J Pathol. 1999;188:56-62.
49. Rusciano D, Lin S, Lorenzoni P, Casella N, Burger MM. Influence of hepatocyte growth factor/scatter factor on the metastatic pheno-type of B16 melanoma cells. Tumour Biol. 1998;19:335-345.
50. Rusciano D, Lorenzoni P, Burger MM. Paracrine growth response as a major determinant in liver-specific colonization by in vivo selected B16 murine melanoma cells. Invasion Metastasis. 1993; 13:212-224.
51. Hendrix MJ, Seftor EA, Seftor RE, et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol. 1998;152:855-863.
52. Gombos DS, Mieler WF. Therapy of uveal melanoma: methods and risk factors associated with treatment. In: Albert DM, Polans AP, eds. Ocular Oncology. New York: Marcel Dekker, Inc.; 2003:321-352.